Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
This study seeks to optimize niosomal formulations of azithromycin (AZ) and evaluate their activities against methicillin-resistant (MRSA). The thin-film hydration was used to prepare niosomes containing various molar ratios of span 60, cholesterol, dicetylphosphate and AZ. Formulation 5, with 5:1:1:1 molar ratio, was optimized based on entrapment efficiency. Solid state analyses and accelerated stability were carried out. The antibacterial properties against MRSA was determined by agar well diffusion method. Physico-chemical characterization of formulation 5 confirmed successful encapsulation of AZ with slightly improved stability at 30°C for 6 months. Niosomal AZ at 0.1% is as effective as vancomycin in inhibiting the growth of MRSA. The antibacterial activities of AZ against MRSA is enhanced when encapsulated within niosomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4155/tde-2022-0034 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!